Cell and gene therapy sector takes aim at market access barriers

8 July 2019

Global cell and gene therapy lobby group The Alliance for Regenerative Medicine (ARM) has published a new report, highlighting key policy proposals to advance the sector.

The document brings together the views of a number of European policymakers, experts and drug developers, providing a comprehensive review of the regulatory and market access framework in Europe, and identifying potential hurdles to adoption.

The ARM argues that, while regulatory frameworks have been implemented to ensure approval of cell and gene therapies, payers and health technology assessment (HTA) bodies have not evolved mechanisms to implement the latest innovations, creating possible barriers post-approval.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK